• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在接受减强度预处理条件后,C 反应蛋白水平可预测异基因干细胞移植后的结果。

C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation.

机构信息

Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden.

出版信息

Int J Hematol. 2010 Jul;92(1):161-7. doi: 10.1007/s12185-010-0632-7. Epub 2010 Jun 25.

DOI:10.1007/s12185-010-0632-7
PMID:20577834
Abstract

The prognostic value of CRP levels before conditioning for allogeneic stem-cell transplantation (ASCT) was evaluated. Reduced-intensity conditioning (RIC) was given to 205 patients and conventional myeloablative conditioning (MAC) to 299 patients. Most patients had an HLA-compatible related or unrelated donor. There were 287 males and 216 females, median age 36 (1-69) years. Most patients received peripheral blood stem cells. Increased CRP levels (>10 mg/L) were detected in 129 patients (26%). Overall survival (OS) and transplant-related mortality (TRM) were worse for RIC patients with elevated CRP (67 vs. 43%, p = 0.005, and 16 vs. 30%, p = 0.036) while no difference was seen in MAC patients. An infection at the start of conditioning was seen in 27 RIC patients. We identified a subgroup of patients with an infection and elevated CRP (n = 16) and these patients had the worst outcome. In multivariate analysis, both infection and elevated CRP was the strongest factor associated with OS (HR 3.27, p < 0.001) and TRM (HR 4.35, p < 0.001). No correlation between any outcome variable and CRP was seen in MAC-treated patients. CRP may be a good prognostic factor for outcome after RIC and ASCT. It should be analyzed before conditioning, especially in patients with coexisting infection since patients with increased CRP and infection seem to have a very poor outcome after ASCT.

摘要

评估了 CRP 水平在异基因干细胞移植(ASCT)预处理前的预后价值。205 例患者接受了低强度预处理(RIC),299 例患者接受了常规清髓性预处理(MAC)。大多数患者有 HLA 相容的亲缘或非亲缘供者。有 287 名男性和 216 名女性,中位年龄为 36(1-69)岁。大多数患者接受了外周血干细胞移植。129 例(26%)患者 CRP 水平升高(>10mg/L)。RIC 患者 CRP 升高(67% vs. 43%,p=0.005)和 TRM(16% vs. 30%,p=0.036)较差,而 MAC 患者无差异。RIC 患者预处理开始时发生感染 27 例。我们确定了一组感染和 CRP 升高的患者(n=16),这些患者的结局最差。多因素分析显示,感染和 CRP 升高均是 OS(HR 3.27,p<0.001)和 TRM(HR 4.35,p<0.001)的最强相关因素。MAC 治疗患者的任何结局变量与 CRP 均无相关性。CRP 可能是 RIC 和 ASCT 后结局的良好预后因素。应在预处理前进行分析,尤其是在伴有合并感染的患者中,因为 CRP 升高合并感染的患者在 ASCT 后似乎预后极差。

相似文献

1
C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation.在接受减强度预处理条件后,C 反应蛋白水平可预测异基因干细胞移植后的结果。
Int J Hematol. 2010 Jul;92(1):161-7. doi: 10.1007/s12185-010-0632-7. Epub 2010 Jun 25.
2
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.急性白血病患者 HLA 全相合同胞异基因造血干细胞移植中,减低剂量预处理方案与清髓性预处理方案的比较结果:单中心经验
Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.
3
Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.接受减低强度预处理异基因造血干细胞移植患者移植前血清C反应蛋白的预后价值
Int J Hematol. 2016 Apr;103(4):444-52. doi: 10.1007/s12185-016-1941-2. Epub 2016 Jan 20.
4
Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.血液系统恶性肿瘤患者异基因干细胞移植的传统与降低强度预处理方案
Eur J Haematol. 2005 Feb;74(2):144-51. doi: 10.1111/j.1600-0609.2004.00360.x.
5
Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.在先前自体移植失败的成年患者中,采用减低剂量预处理进行第二次异基因外周血干细胞移植后,移植相关死亡率较低。
Bone Marrow Transplant. 2002 Jul;30(2):63-8. doi: 10.1038/sj.bmt.1703606.
6
A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.一项前瞻性随机毒性研究比较了接受异基因造血干细胞移植的髓系白血病患者的低强度和清髓性预处理方案。
J Intern Med. 2013 Aug;274(2):153-62. doi: 10.1111/joim.12056. Epub 2013 Mar 25.
7
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.可测量残留疾病、调理方案强度和年龄可预测首次缓解的急性髓系白血病患者接受异基因造血细胞移植的结果:欧洲血液和骨髓移植学会急性白血病工作组对 2292 例患者的注册分析。
Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.
8
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.急性髓系白血病和骨髓增生异常综合征的清髓性与减低强度造血细胞移植
J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.
9
Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.采用减低剂量预处理的异基因造血细胞移植后的第二原发性癌症
Biol Blood Marrow Transplant. 2014 Nov;20(11):1777-84. doi: 10.1016/j.bbmt.2014.07.009. Epub 2014 Jul 17.
10
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.预处理时的C反应蛋白是降低强度异基因造血细胞移植后预后的一个预测指标。
Biol Blood Marrow Transplant. 2008 Nov;14(11):1209-16. doi: 10.1016/j.bbmt.2008.08.004.

引用本文的文献

1
Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis.移植前C反应蛋白作为异基因干细胞移植的预后标志物:一项遵循PRISMA标准的荟萃分析。
Medicine (Baltimore). 2019 Feb;98(8):e14474. doi: 10.1097/MD.0000000000014474.
2
Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT.临床特征、生物标志物及合并症指数作为异基因造血干细胞移植后移植相关死亡率的预测因素
Blood Adv. 2017 Aug 2;1(18):1409-1413. doi: 10.1182/bloodadvances.2017008094. eCollection 2017 Aug 8.
3
Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.

本文引用的文献

1
The clinical importance of bronchoalveolar lavage in allogeneic SCT patients with pneumonia.支气管肺泡灌洗在异基因 SCT 患者肺炎中的临床意义。
Bone Marrow Transplant. 2010 May;45(5):945-50. doi: 10.1038/bmt.2009.268. Epub 2009 Sep 28.
2
Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.与采用清髓性预处理的无关供者移植相比,急性髓系白血病患者采用减低强度预处理的无关供者移植。
J Clin Oncol. 2009 Sep 20;27(27):4570-7. doi: 10.1200/JCO.2008.20.9692. Epub 2009 Aug 3.
3
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
白细胞介素-6在异基因干细胞移植中的作用:其在免疫调节中的潜在重要性及作为治疗靶点的可能性
Front Immunol. 2017 Jun 8;8:667. doi: 10.3389/fimmu.2017.00667. eCollection 2017.
4
Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation.移植前CRP及白细胞介素-6家族细胞因子水平;对异基因干细胞移植后结局的影响
Int J Mol Sci. 2016 Nov 1;17(11):1823. doi: 10.3390/ijms17111823.
5
Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.接受减低强度预处理异基因造血干细胞移植患者移植前血清C反应蛋白的预后价值
Int J Hematol. 2016 Apr;103(4):444-52. doi: 10.1007/s12185-016-1941-2. Epub 2016 Jan 20.
6
Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.移植前血清铁蛋白和 C 反应蛋白水平对异基因造血干细胞移植后慢性移植物抗宿主病发生率的不同影响。
Int J Hematol. 2013 Jan;97(1):109-16. doi: 10.1007/s12185-012-1229-0. Epub 2012 Dec 7.
7
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.大剂量输注吉西他滨联合白消安和马法兰与自体造血干细胞移植治疗难治性淋巴系统恶性肿瘤。
Biol Blood Marrow Transplant. 2012 Nov;18(11):1677-86. doi: 10.1016/j.bbmt.2012.05.011. Epub 2012 May 27.
8
Stem cell transplantation for indolent lymphoma: a reappraisal.惰性淋巴瘤的干细胞移植:再评价。
Blood Rev. 2011 Sep;25(5):223-8. doi: 10.1016/j.blre.2011.05.002.
异基因造血干细胞移植后结局的风险评分:一项回顾性分析
Cancer. 2009 Oct 15;115(20):4715-26. doi: 10.1002/cncr.24531.
4
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.预处理时的C反应蛋白是降低强度异基因造血细胞移植后预后的一个预测指标。
Biol Blood Marrow Transplant. 2008 Nov;14(11):1209-16. doi: 10.1016/j.bbmt.2008.08.004.
5
Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants.造血细胞移植特异性合并症指数能否预测移植结果?一项针对大量脐带血和匹配相关供体移植队列的验证研究。
Biol Blood Marrow Transplant. 2008 Sep;14(9):985-992. doi: 10.1016/j.bbmt.2008.06.008.
6
Recent progress in allogeneic stem cell transplantation.异基因干细胞移植的最新进展
Curr Opin Mol Ther. 2008 Aug;10(4):343-9.
7
Systematic review of the diagnostic accuracy of C-reactive protein to detect bacterial infection in nonhospitalized infants and children with fever.C反应蛋白检测非住院发热婴幼儿细菌感染诊断准确性的系统评价
J Pediatr. 2008 Oct;153(4):570-4. doi: 10.1016/j.jpeds.2008.04.023. Epub 2008 May 27.
8
Polymorphisms of cytokine and innate immunity genes and GVHD.细胞因子和固有免疫基因多态性与移植物抗宿主病
Best Pract Res Clin Haematol. 2008 Jun;21(2):149-64. doi: 10.1016/j.beha.2008.03.004.
9
Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.移植前血清C反应蛋白(CRP)值可能预测异基因造血干细胞移植后的急性移植物抗宿主病和非复发死亡率。
Biol Blood Marrow Transplant. 2008 May;14(5):510-7. doi: 10.1016/j.bbmt.2008.02.008.
10
Lifetime probabilities of hematopoietic stem cell transplantation in the U.S.美国造血干细胞移植的终生概率
Biol Blood Marrow Transplant. 2008 Mar;14(3):316-22. doi: 10.1016/j.bbmt.2007.12.493.